Neuromyelitis Optica Spectrum Disorder | Current Treatment: Physician Insights | US | 2025

NMOSD is a rare, chronic neuroinflammatory disorder marked by optic neuritis and longitudinal extensive transverse myelitis, often leading to repeated attacks and accumulating neurological damage. Recent advancements have led to the development of targeted therapies such as Alexion Pharmaceuticals’ Soliris and Ultomiris, Roche / Genentech’s Enspryng, and Amgen’s Uplizna for AQP4-positive NMOSD. However, owing to safety concerns and high costs, off-label therapies such as rituximab, corticosteroids, and immunosuppressants are frequently used, especially in early treatment stages (for both acute and long-term) and for seronegative patients. Ongoing research aims to develop effective therapies for seronegative patients, gather long-term safety data, and identify predictive biomarkers to further improve NMOSD management.

QUESTIONS ANSWERED

• How does physician prescribing of current treatment options vary based on their antibody status, i.e., for AQP4-positive and seronegative patients?
• What is the patient share of key therapies, including approved monoclonal antibodies, Soliris, Ultomiris, Enspryng, and Uplizna, in the United States, according to the surveyed neurologists?
• What are the clinical characteristics that physicians consider when choosing each biologic for their AQP4-positive NMOSD patients?
• What are the key drivers and obstacles determining current prescribing patterns in the treatment of NMOSD patients?

PRODUCT DESCRIPTION Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.

CONTENT HIGHLIGHTS

Geography: United States

Primary research: Survey of 99 U.S. Neurologists

Key drugs covered: Enspryng (satralizumab), rituximab, Soliris (eculizumab), Uplizna (inebilizumab), Ultomiris (ravulizumab)